.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Federal Trade Commission
Colorcon
Harvard Business School
Covington
Fuji
Chinese Patent Office
Accenture
Cantor Fitzgerald

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076004

« Back to Dashboard
NDA 076004 describes ETODOLAC, which is a drug marketed by Sandoz, Apotex Inc, Mylan Pharms Inc, Teva, Mylan, Apotex, Oxford Pharms, Ani Pharms Inc, Ranbaxy Labs Ltd, Eci Pharms Llc, Watson Labs Florida, Zydus Pharms Usa Inc, Idt Australia Ltd, Chartwell Molecules, Watson Labs, Taro, Taro Pharm Inds, Ivax Sub Teva Pharms, and Actavis Elizabeth, and is included in thirty-three NDAs. It is available from thirty-nine suppliers. Additional details are available on the ETODOLAC profile page.

The generic ingredient in ETODOLAC is etodolac. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the etodolac profile page.

Summary for 076004

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 076004

Medical Subject Heading (MeSH) Categories for 076004

Suppliers and Packaging for NDA: 076004

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ETODOLAC
etodolac
TABLET;ORAL 076004 ANDA KAISER FOUNDATION HOSPITALS 0179-0207 0179-0207-70 30 TABLET, FILM COATED in 1 BOX, UNIT-DOSE (0179-0207-70)
ETODOLAC
etodolac
TABLET;ORAL 076004 ANDA STAT Rx USA LLC 42549-511 42549-511-30 30 TABLET, FILM COATED in 1 BOTTLE (42549-511-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength400MG
Approval Date:Dec 3, 2002TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG
Approval Date:Dec 3, 2002TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cerilliant
QuintilesIMS
Chubb
McKesson
Queensland Health
Boehringer Ingelheim
Colorcon
Healthtrust
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot